CN107779438B - 一种放疗耐受肺癌细胞系及其构建方法和应用 - Google Patents
一种放疗耐受肺癌细胞系及其构建方法和应用 Download PDFInfo
- Publication number
- CN107779438B CN107779438B CN201710873780.4A CN201710873780A CN107779438B CN 107779438 B CN107779438 B CN 107779438B CN 201710873780 A CN201710873780 A CN 201710873780A CN 107779438 B CN107779438 B CN 107779438B
- Authority
- CN
- China
- Prior art keywords
- radiotherapy
- lung cancer
- cell line
- cells
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 46
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 46
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 46
- 238000010276 construction Methods 0.000 title abstract description 6
- 238000001959 radiotherapy Methods 0.000 claims abstract description 51
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims abstract description 12
- 201000005249 lung adenocarcinoma Diseases 0.000 claims abstract description 12
- 230000005855 radiation Effects 0.000 claims abstract description 9
- 230000007246 mechanism Effects 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 abstract description 8
- 230000001678 irradiating effect Effects 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract description 4
- 230000008261 resistance mechanism Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 101
- 230000004083 survival effect Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000003439 radiotherapeutic effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710873780.4A CN107779438B (zh) | 2017-09-25 | 2017-09-25 | 一种放疗耐受肺癌细胞系及其构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710873780.4A CN107779438B (zh) | 2017-09-25 | 2017-09-25 | 一种放疗耐受肺癌细胞系及其构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107779438A CN107779438A (zh) | 2018-03-09 |
CN107779438B true CN107779438B (zh) | 2020-03-27 |
Family
ID=61433655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710873780.4A Active CN107779438B (zh) | 2017-09-25 | 2017-09-25 | 一种放疗耐受肺癌细胞系及其构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107779438B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110368591A (zh) * | 2019-08-05 | 2019-10-25 | 爱心科研股份公司 | 微电波治癌烤疗仪 |
CN110878284A (zh) * | 2019-10-12 | 2020-03-13 | 南方医科大学南方医院 | 等差剂量梯度辐射存活或抵抗肺癌细胞模型及构建与应用 |
CN110628703A (zh) * | 2019-10-30 | 2019-12-31 | 复旦大学附属金山医院 | 一种放射性肺损伤体外细胞模型及其构建方法和应用 |
CN113621574B (zh) * | 2021-08-13 | 2023-09-01 | 四川大学华西医院 | 一种人胶质母细胞瘤放疗抵抗细胞株及其应用 |
CN113583963B (zh) * | 2021-08-13 | 2023-07-21 | 四川大学华西医院 | 一种小鼠肉瘤放疗抵抗细胞株及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102517254B (zh) * | 2011-12-31 | 2013-07-24 | 广州呼吸疾病研究所 | 一种来源于人放化疗后复发小细胞肺癌淋巴结的细胞株及其制备方法 |
CN104962548A (zh) * | 2015-06-29 | 2015-10-07 | 徐州医学院 | 一种肺癌辐射抗性细胞株的构建方法 |
CN106138082A (zh) * | 2016-07-26 | 2016-11-23 | 滨州医学院 | 一种增强肺癌放疗敏感性的rna核酸及应用 |
CN107099586B (zh) * | 2017-04-25 | 2020-03-10 | 北京市化工职业病防治院 | 检测肺癌细胞对x射线放射敏感性的方法、芯片及用途 |
-
2017
- 2017-09-25 CN CN201710873780.4A patent/CN107779438B/zh active Active
Non-Patent Citations (3)
Title |
---|
吉非替尼及培美曲塞对EGFR19外显子突变的人肺腺癌PC9细胞株的放射效应的实验研究;赖祥丽;《万方中国学位论文全文数据库》;20170922;摘要、第8页材料和方法、第32页倒数第1段 * |
庄喜兵 等.放射抗拒Lewis肺癌细胞系的建立.《中华放射医学与防护杂志》.2015,第35卷(第11期),摘要、第805页右栏第2段-第806页左栏第3段. * |
放射抗拒Lewis肺癌细胞系的建立;庄喜兵 等;《中华放射医学与防护杂志》;20151130;第35卷(第11期);摘要、第805页右栏第2段-第806页左栏第3段 * |
Also Published As
Publication number | Publication date |
---|---|
CN107779438A (zh) | 2018-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107779438B (zh) | 一种放疗耐受肺癌细胞系及其构建方法和应用 | |
Yang et al. | Neoplastic cell transformation by heavy charged particles | |
CN110055218B (zh) | 一种人工改造自然杀伤性细胞及其制备与应用 | |
Fernandez-Palomo et al. | Bystander effects in tumor-free and tumor-bearing rat brains following irradiation by synchrotron X-rays | |
CN103627673A (zh) | 一种人脑胶质瘤细胞系及其建立方法和应用 | |
CN110878284A (zh) | 等差剂量梯度辐射存活或抵抗肺癌细胞模型及构建与应用 | |
CN107541494B (zh) | 一种人胆管癌细胞系及其应用 | |
Wheldon et al. | The radiosensitivity of human neuroblastoma cells estimated from regrowth curves of multicellular tumour spheroids | |
Fowler et al. | Dose-effect relationships for radiation damage to organized tissues | |
Bianconi et al. | Pretreatment of mesenchymal stem cells with electrical stimulation as a strategy to improve bone tissue engineering outcomes | |
KR100783199B1 (ko) | 인간의 뇌 암 조직으로부터 확립된 신규 암 줄기 세포주gbm 2 | |
CN111358794A (zh) | 一种用于治疗非小细胞肺癌的药物或试剂盒 | |
WO2021249441A1 (zh) | 一对具有相同遗传背景和不同转移潜能的肺癌细胞株及其制备方法和用途 | |
CN101186899A (zh) | 一种应用于肿瘤细胞和干细胞共培养的新方法 | |
CN110438081B (zh) | 人套细胞淋巴瘤恶性克隆细胞株及其建立方法和应用 | |
CN109294998B (zh) | 一种rff1细胞 | |
CN114058584A (zh) | 一种临床用自然杀伤细胞的制备方法 | |
CN113621574B (zh) | 一种人胶质母细胞瘤放疗抵抗细胞株及其应用 | |
CN108467855B (zh) | 新的肺特异性转移肝癌细胞及其制备 | |
CN110628703A (zh) | 一种放射性肺损伤体外细胞模型及其构建方法和应用 | |
CN113583963B (zh) | 一种小鼠肉瘤放疗抵抗细胞株及其应用 | |
CN107541495B (zh) | 一种fgf19过表达的人肝癌细胞系及其应用 | |
CN112522262B (zh) | 一种与胰腺癌相关的tRF及其应用 | |
CN108103023A (zh) | 人直肠癌原代细胞及其应用 | |
CN115029316B (zh) | 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Shirong Inventor after: Zhang Jingjing Inventor after: Zhao Yanyan Inventor after: Ma Shenglin Inventor after: Wu Qiong Inventor after: Xu Yasi Inventor after: Huang Haixiu Inventor before: Zhang Jingjing Inventor before: Zhang Shirong Inventor before: Zhao Yanyan Inventor before: Ma Shenglin Inventor before: Wu Qiong Inventor before: Xu Yasi Inventor before: Huang Haixiu |
|
GR01 | Patent grant | ||
GR01 | Patent grant |